[
  {
    "ts": null,
    "headline": "Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® (nipocalimab-aahu) as the first-ever treatment for patients with warm autoimmune hemolytic anemia (wAIHA).b This rare and serious autoantibody disease affects approximately 1 in 8,000 in the United States and currently has no approved treatments despite substantial unmet need.1 The condition is associated w",
    "url": "https://finnhub.io/api/news?id=feda48297a9f866da1f863dfb5f2b415ae5f6ea4c1d2c151b68f1e5d8da0cabd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771966980,
      "headline": "Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)",
      "id": 139201558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® (nipocalimab-aahu) as the first-ever treatment for patients with warm autoimmune hemolytic anemia (wAIHA).b This rare and serious autoantibody disease affects approximately 1 in 8,000 in the United States and currently has no approved treatments despite substantial unmet need.1 The condition is associated w",
      "url": "https://finnhub.io/api/news?id=feda48297a9f866da1f863dfb5f2b415ae5f6ea4c1d2c151b68f1e5d8da0cabd"
    }
  },
  {
    "ts": null,
    "headline": "2026 Stock Market Crash Coming? 3 Best ETFs to Protect You Now",
    "summary": "History shows that midterm election years aren’t always great years for the S&P 500. Are you properly protected against the full blow of a 2026 market crash? Probably not, but there are action steps you can take today to brace for the impact of a potential market collapse. Fortunately, there are safety-first exchange traded funds ... 2026 Stock Market Crash Coming? 3 Best ETFs to Protect You Now",
    "url": "https://finnhub.io/api/news?id=4905e7e4f95a4fda4f59909901262b250ceb6c670ba12bced215926aaa0bb460",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771961760,
      "headline": "2026 Stock Market Crash Coming? 3 Best ETFs to Protect You Now",
      "id": 139201556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "History shows that midterm election years aren’t always great years for the S&P 500. Are you properly protected against the full blow of a 2026 market crash? Probably not, but there are action steps you can take today to brace for the impact of a potential market collapse. Fortunately, there are safety-first exchange traded funds ... 2026 Stock Market Crash Coming? 3 Best ETFs to Protect You Now",
      "url": "https://finnhub.io/api/news?id=4905e7e4f95a4fda4f59909901262b250ceb6c670ba12bced215926aaa0bb460"
    }
  },
  {
    "ts": null,
    "headline": "Industry Group Rotation Since The Last Market High",
    "summary": "Industry Group Rotation Since The Last Market High",
    "url": "https://finnhub.io/api/news?id=f863a16297c057ee7e339e7eff98de19fcc6990d65019a84a4097e33baac0141",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771958700,
      "headline": "Industry Group Rotation Since The Last Market High",
      "id": 139202289,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f863a16297c057ee7e339e7eff98de19fcc6990d65019a84a4097e33baac0141"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer's simple framework for identifying winners in a market fearful of AI disruption",
    "summary": "CNBC's Jim Cramer said Tuesday that investors should be able to answer this question about stocks they own in this market.",
    "url": "https://finnhub.io/api/news?id=e937f0fc8bd46c91735eb2a935dbda22549c0055a908d01e258cf403470cab9c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771957378,
      "headline": "Jim Cramer's simple framework for identifying winners in a market fearful of AI disruption",
      "id": 139212515,
      "image": "https://image.cnbcfm.com/api/v1/image/107097082-1659388885412-gettyimages-1242252498-CATERPILLAR_EARNS.jpeg?v=1771972817&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "CNBC's Jim Cramer said Tuesday that investors should be able to answer this question about stocks they own in this market. ",
      "url": "https://finnhub.io/api/news?id=e937f0fc8bd46c91735eb2a935dbda22549c0055a908d01e258cf403470cab9c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Submits Supplemental Biologics License Application For Autoimmune Hemolytic Anemia Treatment Approval To FDA",
    "summary": "Johnson &amp; Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® (nipocalimab-aahu)",
    "url": "https://finnhub.io/api/news?id=e679878822aa946d7f3e886132c5ce3846862342e7c5a4151b0a7bb45b9bb380",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771953500,
      "headline": "Johnson & Johnson Submits Supplemental Biologics License Application For Autoimmune Hemolytic Anemia Treatment Approval To FDA",
      "id": 139207387,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "Johnson &amp; Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® (nipocalimab-aahu)",
      "url": "https://finnhub.io/api/news?id=e679878822aa946d7f3e886132c5ce3846862342e7c5a4151b0a7bb45b9bb380"
    }
  },
  {
    "ts": null,
    "headline": "Global Cosmetics Market Competitive Landscape Report 2025: Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The Global Cosmetics Market is set for significant growth, projected to leap from US$ 346.1 billion in 2025 to US$ 526.74 billion by 2033, with a CAGR of 5.39%. This growth is driven by soaring demand for vegan cosmetics, product innovation, personal grooming awareness, and e-commerce expansion. Major players like Coty, P&G, Estee Lauder, Colgate-Palmolive, and Johnson & Johnson lead the market. As trends emphasize health, organic, and cruelty-free products, companies like Revlon and Beiersdorf",
    "url": "https://finnhub.io/api/news?id=6b15dd4a69819676306b00c0d5ff1007052ed2fd9034553652911c7ce96c2bef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771950180,
      "headline": "Global Cosmetics Market Competitive Landscape Report 2025: Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Global Cosmetics Market is set for significant growth, projected to leap from US$ 346.1 billion in 2025 to US$ 526.74 billion by 2033, with a CAGR of 5.39%. This growth is driven by soaring demand for vegan cosmetics, product innovation, personal grooming awareness, and e-commerce expansion. Major players like Coty, P&G, Estee Lauder, Colgate-Palmolive, and Johnson & Johnson lead the market. As trends emphasize health, organic, and cruelty-free products, companies like Revlon and Beiersdorf",
      "url": "https://finnhub.io/api/news?id=6b15dd4a69819676306b00c0d5ff1007052ed2fd9034553652911c7ce96c2bef"
    }
  },
  {
    "ts": null,
    "headline": "OTC Artificial Tears Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The OTC Artificial Tears market is projected to expand from USD 4.93 billion in 2025 to USD 7.22 billion by 2033, growing at a CAGR of 4.88%. This growth is driven by increased accessibility in public spaces, rising dry eye syndrome cases due to aging and digital exposure, and heightened awareness of eye health. Artificial tears mimic natural tears to relieve dry eyes, making them integral to eye care routines. Key players, including AbbVie, Akorn, Alcon, Bausch Health, and Johnson & Johnson, ar",
    "url": "https://finnhub.io/api/news?id=8b985a8f59c2f1e5b402b5e6f08cb5d8775c91271d2d8191c4236b0adfd43628",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771949700,
      "headline": "OTC Artificial Tears Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The OTC Artificial Tears market is projected to expand from USD 4.93 billion in 2025 to USD 7.22 billion by 2033, growing at a CAGR of 4.88%. This growth is driven by increased accessibility in public spaces, rising dry eye syndrome cases due to aging and digital exposure, and heightened awareness of eye health. Artificial tears mimic natural tears to relieve dry eyes, making them integral to eye care routines. Key players, including AbbVie, Akorn, Alcon, Bausch Health, and Johnson & Johnson, ar",
      "url": "https://finnhub.io/api/news?id=8b985a8f59c2f1e5b402b5e6f08cb5d8775c91271d2d8191c4236b0adfd43628"
    }
  },
  {
    "ts": null,
    "headline": "What Johnson & Johnson (JNJ)'s Prostate Cancer Drug Lawsuit Means For Shareholders",
    "summary": "In February 2026, Bayer filed a lawsuit in U.S. federal court accusing Johnson & Johnson and Janssen Biotech of falsely promoting the superiority of prostate cancer drug ERLEADA over Bayer’s NUBEQA using what Bayer claims is a flawed real‑world evidence analysis. The case not only challenges specific efficacy claims but also spotlights how drugmakers use real‑world data in competitive oncology markets, potentially influencing future promotional standards across the sector. We’ll now examine...",
    "url": "https://finnhub.io/api/news?id=e8f4a097b0ddd02df149c89fe64c7e1d255b0a0c50d77b50f61237af09dbf9a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771945709,
      "headline": "What Johnson & Johnson (JNJ)'s Prostate Cancer Drug Lawsuit Means For Shareholders",
      "id": 139197295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In February 2026, Bayer filed a lawsuit in U.S. federal court accusing Johnson & Johnson and Janssen Biotech of falsely promoting the superiority of prostate cancer drug ERLEADA over Bayer’s NUBEQA using what Bayer claims is a flawed real‑world evidence analysis. The case not only challenges specific efficacy claims but also spotlights how drugmakers use real‑world data in competitive oncology markets, potentially influencing future promotional standards across the sector. We’ll now examine...",
      "url": "https://finnhub.io/api/news?id=e8f4a097b0ddd02df149c89fe64c7e1d255b0a0c50d77b50f61237af09dbf9a1"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?",
    "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=acc62f9fbe64c14c9b1e4fe1a8c68f9eaadafa86e887fd767c6f763e228e0c36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771943406,
      "headline": "Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?",
      "id": 139198792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=acc62f9fbe64c14c9b1e4fe1a8c68f9eaadafa86e887fd767c6f763e228e0c36"
    }
  },
  {
    "ts": null,
    "headline": "Operational Security Solutions (OSS) Partners With J&J Merchant Services to Expand Capital Access and Compliant Payment Infrastructure for Highly Regulated Industries",
    "summary": "Strategic Partnership Delivers Integrated Lending, POS, Merchant Processing and ATM Solutions to Cannabis and High-Risk Operators FRESNO, CA - February 24, 2026 (NEWMEDIAWIRE) - Operational Security Solutions (OSS), a leading provider of secure cash ...",
    "url": "https://finnhub.io/api/news?id=94d6f753d8ec172dccb9d26ac0ffe0fbdcce671b019ad60804fc95dc9d2f48e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771940580,
      "headline": "Operational Security Solutions (OSS) Partners With J&J Merchant Services to Expand Capital Access and Compliant Payment Infrastructure for Highly Regulated Industries",
      "id": 139194404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Strategic Partnership Delivers Integrated Lending, POS, Merchant Processing and ATM Solutions to Cannabis and High-Risk Operators FRESNO, CA - February 24, 2026 (NEWMEDIAWIRE) - Operational Security Solutions (OSS), a leading provider of secure cash ...",
      "url": "https://finnhub.io/api/news?id=94d6f753d8ec172dccb9d26ac0ffe0fbdcce671b019ad60804fc95dc9d2f48e1"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson Stock Outperforming the Nasdaq?",
    "summary": "Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=6c529d0544adc30be09d209e6fc385f861c41717cf074d25ab9eff2754a279d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771938115,
      "headline": "Is Johnson & Johnson Stock Outperforming the Nasdaq?",
      "id": 139198793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=6c529d0544adc30be09d209e6fc385f861c41717cf074d25ab9eff2754a279d7"
    }
  },
  {
    "ts": null,
    "headline": "Vision Care Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The Vision Care market is expected to grow from US$81.23 billion in 2025 to US$117.75 billion by 2033, at a CAGR of 4.75%. Factors driving this growth include enhanced access to healthcare, increased awareness of eye health, and innovations in contact lenses, eyeglass frames, and lens materials. The demand for vision care is soaring globally due to rising digital eye strain and age-related conditions, while healthcare initiatives highlight the importance of regular check-ups. Leading companies l",
    "url": "https://finnhub.io/api/news?id=d4b4d42f87c3752945505f70da0c9b7f342bb129dc95a40b2e017cd6ef6500e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771932540,
      "headline": "Vision Care Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139193236,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Vision Care market is expected to grow from US$81.23 billion in 2025 to US$117.75 billion by 2033, at a CAGR of 4.75%. Factors driving this growth include enhanced access to healthcare, increased awareness of eye health, and innovations in contact lenses, eyeglass frames, and lens materials. The demand for vision care is soaring globally due to rising digital eye strain and age-related conditions, while healthcare initiatives highlight the importance of regular check-ups. Leading companies l",
      "url": "https://finnhub.io/api/news?id=d4b4d42f87c3752945505f70da0c9b7f342bb129dc95a40b2e017cd6ef6500e2"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Sues J&J Over 51% Claim",
    "summary": "Cancer Drug Survival Data Dispute Intensifies",
    "url": "https://finnhub.io/api/news?id=ec6a0b2e4ceac8e7708c997687a1e00356379fc271f51ce42817c00a2d6741e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771931787,
      "headline": "Bayer Sues J&J Over 51% Claim",
      "id": 139193237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Cancer Drug Survival Data Dispute Intensifies",
      "url": "https://finnhub.io/api/news?id=ec6a0b2e4ceac8e7708c997687a1e00356379fc271f51ce42817c00a2d6741e1"
    }
  },
  {
    "ts": null,
    "headline": "J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push",
    "summary": "Johnson & Johnson (NYSE:JNJ) is reportedly preparing for a potential sale of its orthopedics unit, DePuy Synthes, as it advances plans to separate the business. In 2011, the medtech giant acquired DePuy Synthes for a massive $21.3 billion. In October 2025, Johnson & Johnson said it plans to separate its Orthopedics business to enhance the strategic and operational focus. Johnson & Johnson said it is targeting completion within 18 to 24 months. Don't Miss: Explore the Fire-Safe Energy Storage Com",
    "url": "https://finnhub.io/api/news?id=e9801dad83cf449ebafe15f274372515e3dff0d34c09edc1784dc28b41de9f09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771929923,
      "headline": "J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push",
      "id": 139193238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is reportedly preparing for a potential sale of its orthopedics unit, DePuy Synthes, as it advances plans to separate the business. In 2011, the medtech giant acquired DePuy Synthes for a massive $21.3 billion. In October 2025, Johnson & Johnson said it plans to separate its Orthopedics business to enhance the strategic and operational focus. Johnson & Johnson said it is targeting completion within 18 to 24 months. Don't Miss: Explore the Fire-Safe Energy Storage Com",
      "url": "https://finnhub.io/api/news?id=e9801dad83cf449ebafe15f274372515e3dff0d34c09edc1784dc28b41de9f09"
    }
  },
  {
    "ts": null,
    "headline": "Cataract Surgery Devices Market Companies Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
    "summary": "The cataract surgery devices market is poised for growth, projected to expand from USD 9.25 billion in 2025 to USD 12.47 billion by 2033, with a CAGR of 3.80%. Key drivers include rising cataract incidences among aging populations, technological advancements, and increased awareness of early intervention. Devices such as phacoemulsification systems, femtosecond lasers, and ophthalmic viscosurgical tools enhance precision and recovery times in surgeries. Major players like Alcon, Johnson & Johnso",
    "url": "https://finnhub.io/api/news?id=870606bcb6af4f1435b72d6aaf590c92aa2cfe43ad12d4e08caaa0dd721a28be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771923720,
      "headline": "Cataract Surgery Devices Market Companies Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
      "id": 139192432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The cataract surgery devices market is poised for growth, projected to expand from USD 9.25 billion in 2025 to USD 12.47 billion by 2033, with a CAGR of 3.80%. Key drivers include rising cataract incidences among aging populations, technological advancements, and increased awareness of early intervention. Devices such as phacoemulsification systems, femtosecond lasers, and ophthalmic viscosurgical tools enhance precision and recovery times in surgeries. Major players like Alcon, Johnson & Johnso",
      "url": "https://finnhub.io/api/news?id=870606bcb6af4f1435b72d6aaf590c92aa2cfe43ad12d4e08caaa0dd721a28be"
    }
  },
  {
    "ts": null,
    "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster",
    "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
    "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771895025,
      "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster ",
      "id": 139198069,
      "image": "https://image.cnbcfm.com/api/v1/image/108268945-1771917055711-gettyimages-1583281302-uk_20230807_ukr61.jpeg?v=1771917103&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
      "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d"
    }
  }
]